These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33527618)

  • 21. Are dissecting cellulitis and hidradenitis suppurativa different diseases?
    Federico A; Rossi A; Caro G; Magri F; Muscianese M; Di Fraia M; Carlesimo M
    Clin Dermatol; 2021; 39(3):496-499. PubMed ID: 34518010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unusual pyodermas (hidrosadenitis suppurativa, acne conglobata, dissecting cellulitis of the scalp).
    KIERLAND RR
    Minn Med; 1951 Apr; 34(4):319-25; passim. PubMed ID: 14826630
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hidradenitis suppurativa/acne inversa in the genitoanal region].
    Hessam S; Bechara FG
    Hautarzt; 2020 Apr; 71(4):256-262. PubMed ID: 32077977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study.
    Ring HC; Yao Y; Maul JT; Ingram JR; Frew JW; Thorsen J; Nielsen ML; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
    Br J Dermatol; 2022 Oct; 187(4):523-530. PubMed ID: 35603888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
    Samycia M; Brassard A
    J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.
    Zouboulis CC; Bechara FG; Dickinson-Blok JL; Gulliver W; Horváth B; Hughes R; Kimball AB; Kirby B; Martorell A; Podda M; Prens EP; Ring HC; Tzellos T; van der Zee HH; van Straalen KR; Vossen ARJV; Jemec GBE
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):19-31. PubMed ID: 30176066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma.
    Scheinfeld N
    Dermatol Online J; 2014 Mar; 20(3):. PubMed ID: 24656278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two diseases one remedy? Systemic amyloidosis secondary to hidradenitis suppurativa: Treatment with infliximab.
    Özer İ; Karaçin C; Adışen E; Güz G; Ali Gürer M
    Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27862787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Boils at Frictional Locations in a Patient with Hidradenitis Suppurativa.
    Boer J; Mihajlovic D
    Acta Dermatovenerol Croat; 2016 Dec; 24(4):303-304. PubMed ID: 28128084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
    Porter ML; Golbari NM; Lockwood SJ; Kimball AB
    Semin Cutan Med Surg; 2018 Sep; 37(3):182-189. PubMed ID: 30215636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of biological treatments in patients with hidradenitis suppurativa.
    Martin-Ezquerra G; Masferrer E; Pujol RM
    G Ital Dermatol Venereol; 2017 Aug; 152(4):373-378. PubMed ID: 27982551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy.
    Vural S; Gündoğdu M; Akay BN; Boyvat A; Erdem C; Koçyiğit P; Bostancı S; Sanli H; Kundakci N
    Dermatol Ther; 2019 Sep; 32(5):e13003. PubMed ID: 31237104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report.
    Gutierrez E; Issa N; Resnik B
    J Drugs Dermatol; 2022 Dec; 21(12):1358-1360. PubMed ID: 36468954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
    Dumont LM; Landman C; Sokol H; Beaugerie L; Cosnes J; Seksik P; Guégan S;
    Aliment Pharmacol Ther; 2020 Jul; 52(2):303-310. PubMed ID: 32525586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complications of hidradenitis suppurativa.
    Yuan JT; Naik HB
    Semin Cutan Med Surg; 2017 Jun; 36(2):79-85. PubMed ID: 28538749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.
    Nazary M; van der Zee HH; Prens EP; Folkerts G; Boer J
    Eur J Pharmacol; 2011 Dec; 672(1-3):1-8. PubMed ID: 21930119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?
    Ghanian S; Yamanaka-Takaichi M; Naik HB; Alavi A
    Am J Clin Dermatol; 2022 Mar; 23(2):167-176. PubMed ID: 34990004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.